APERIMProject reference: 633592
Funded under :
APERIM: Advanced bioinformatics platform for PERsonalised cancer IMmunotherapy
Total cost:EUR 2 999 287,5
EU contribution:EUR 2 999 287,5
Call for proposal:H2020-PHC-2014-two-stageSee other projects for this call
Funding scheme:RIA - Research and Innovation action
Cancer treatment platforms that involve the use of the adaptive immune system have demonstrated profound tumour regressions including complete cure. Importantly, technological advances in next-generation sequencing (NGS) allow for the first time the development of personalised cancer immunotherapies that target patient specific mutations. However, clinical application is currently hampered by specific bottlenecks in bioinformatics, which we aim to address in this proposal.
The overall objective of our trans-disciplinary network of leading experts in bioinformatics and cancer immunology is to develop an Advanced bioinformatics platform for PERrsonalised cancer IMmunotherapy (APERIM). Specifically we aim to develop:
1) database for the integration of NGS data, images of whole tissue slides of tumour sections, and clinical data. To enhance the usability and the data sharing we will use semantic web technologies, and will provide standardised interfaces to a set of analytical tools.
2) tools for automated quantification of tumour-infiltrating lymphocytes using whole tissue slide images and NGS data for patient stratification.
3) analytical pipeline for NGS-guided individualised cancer vaccines including crucial NGS data analysis and epitope selection components for the selection of vaccination targets.
4) a method for deriving T-cell receptor (TCR) sequences from NGS data and predicting TCR specificity.
We will achieve these aims using unique training and validation datasets available to the consortium. We will develop user-friendly software modules as well as analytical standard operating procedures for clinical use, and apply the bioinformatics platform in clinical settings. The bioinformatics platform will considerably accelerate the clinical translation and maximise the accessibility and utility of biomedical data in research and medicine.
EU contribution: EUR 420 540
EU contribution: EUR 185 262,5
C/ MELCHIOR FERNANDEZ ALMAGRO 3
EU contribution: EUR 247 500
EU contribution: EUR 249 000
3584 CS UTRECHT
EU contribution: EUR 135 250
Zerotinovo namesti 9
60177 BRNO STRED
EU contribution: EUR 258 000
101 Rue de Tolbiac
EU contribution: EUR 347 250
EU contribution: EUR 279 000
1066 CX AMSTERDAM
EU contribution: EUR 327 000
EU contribution: EUR 307 125
EU contribution: EUR 243 360
KARL KAPFERER STRASSE 5